Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

NuGen Medical Devices Inc. (79O.F)

Compare
0.0240
-0.0060
(-20.00%)
At close: April 1 at 8:03:29 AM GMT+2
Loading Chart for 79O.F
  • Previous Close 0.0300
  • Open 0.0240
  • Bid 0.0250 x --
  • Ask 0.0422 x --
  • Day's Range 0.0240 - 0.0240
  • 52 Week Range 0.0232 - 0.1090
  • Volume 29,500
  • Avg. Volume 14,017
  • Market Cap (intraday) 5.225M
  • Beta (5Y Monthly) 2.62
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date Apr 28, 2025 - May 2, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

NuGen Medical Devices Inc., a specialty medical device company, develops and commercializes novel drug delivery technologies in Europe, Asia, North America, and internationally. The company offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, semaglutide, and growth and fertility hormone, as well as DNA and conventional/pediatric vaccines. It also provides InsuJet system that focuses on servicing the diabetic community; and V5, V6, V7, and V8 InsuJet injectors. NuGen Medical Devices Inc. is headquartered in Toronto, Canada.

www.nugenmd.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 79O.F

View More

Performance Overview: 79O.F

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

79O.F
52.00%
S&P/TSX Composite index (^GSPTSE)
1.68%

1-Year Return

79O.F
68.42%
S&P/TSX Composite index (^GSPTSE)
12.84%

3-Year Return

79O.F
86.14%
S&P/TSX Composite index (^GSPTSE)
14.03%

5-Year Return

79O.F
83.57%
S&P/TSX Composite index (^GSPTSE)
94.41%

Compare To: 79O.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 79O.F

View More

Valuation Measures

Annual
As of 3/31/2025
  • Market Cap

    6.33M

  • Enterprise Value

    12.73M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.75

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    25.84

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -33.95%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    762.79k

  • Net Income Avi to Common (ttm)

    -8.31M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.34M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.56M

Research Analysis: 79O.F

View More

Company Insights: 79O.F

Research Reports: 79O.F

View More

People Also Watch